BioNTech AG acquires EUFETS AG

Idar-Oberstein/Germany, June 3, 2009. BioNTech AG (Mainz, Germany),
a biotech company developing novel personalized immunotherapy
approaches today announced the acquisition of all shares of EUFETS AG
from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a
fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in
GMP and GLP services for innovative biopharmaceutical approaches.
Under the new owner, EUFETS will retain all facilities, employees and
contractual obligations of the former company.
"The investment in EUFETS is an excellent fit endowing BioNTech with
synergistic platforms and complementary expertise" commented Prof.
Dr. Ugur Sahin, CEO of BioNTech AG, and Dr. Klaus Kühlcke, vice
president operations of EUFETS, adding, "We are interested to
progress EUFETS into a center of excellence that addresses the needs
of individualized medicine by developing and providing a wide range
of high-quality GMP/GLP services for innovative approaches such as
recombinant vaccines, cell based therapies,
gene- and immunotherapies. Helmut Jeggle, chair of the supervisory
board of BioNTech noted "The acquisition of EUFETS, similar to the
purchase of JPT Berlin two weeks ago, is a logical step for our
long-term strategy to build an excellent and competitive company for
biopharmaceutical drug and biomarker development."

About BioNTech AG

BioNTech (Biopharmaceutical New Technologies) AG is a
"spin-off"-company of the Johannes Gutenberg University located in
Mainz, Germany. The company, which is financed by AT Impf GmbH (a
wholly owned company of Dr. Andreas & Dr. Thomas Strüngmann) and MIG
Fonds, owns four subsidiaries, Ribological, UniCell, Tulip and
TheraCode. BioNTech is dedicated to the development of innovative
molecular immunotherapies and biomarker based diagnostic approaches
for individualized treatment of cancer and other severe human
diseases.

About EUFETS AG

EUFETS AG specializes in providing services in the area of
development and manufacture of cell-based and gene-based
therapeutics. EUFETS possesses comprehensive know-how in the
development and production of stem cell preparations, retroviral
vectors and genetic modification of primary cells and cell lines.
Since 1999 the company is GMP certified and meanwhile recognized as
the leading producer of retroviral vectors for clinical trials in
Europe. Since 2003, EUFETS has also been certified as a GLP
laboratory, providing a comprehensive package of special analytical
in vitro assays facilitating clients' preclinical programs, including
the testing of bioactive drug substances such as therapeutic
antibodies.

For further information please contact:

BioNTech AG
Prof. Dr. Ugur Sahin
Chief Executive Officer
BioNTech AG
Langenbeckstr. 8
D-55131 Mainz/Germany
Email: sahin@uni-mainz.de
Tel: +49 (0) 6131 - 3933456
Fax: +49 (0) 6131 - 3933343

EUFETS AG
Dr. Klaus Kuehlcke
Vice President Operations
Eufets Aktiengesellschaft
Vollmersbachstr. 66
D-55743 Idar-Oberstein/Germany
Email: klaus.kuehlcke@fresenius-biotech.com
Tel.: +49 (0) 6781 - 9855219
Fax: +49 (0) 6781 - 9855237

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.